Structural Basis for Postfusion-Specific Binding to the Respiratory Syncytial Virus F Protein by the Canonical Antigenic Site I Antibody 131–2a
Open Access
- 22 July 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (8) , 2357-2366
Abstract
The respiratory syncytial virus (RSV) fusion (F) protein is a major target of antiviral antibodies following natural infection or vaccination and is responsible for mediating fusion between the viral envelope and the host membrane. The fusion process is driven by a large-scale conformational change in F, switching irreversibly from the metastable prefusion state to the stable postfusion conformation. Previous research has identified six distinct antigenic sites in RSV-F, termed sites Ø, I, II, III, IV, and V. Of these, only antigenic site I is fully specific to the postfusion conformation of F. A monoclonal antibody 131-2a that specifically targets postfusion F has been widely used as a research tool to probe for postfusion F and to define antigenic site I in serological studies, yet its sequence and precise epitope have remained unknown. Here, we use mass spectrometry-based de novo sequencing of 131-2a to reverse engineer a recombinant product and study the epitope to define antigenic site I with molecular detail, revealing the structural basis for the antibody's specificity toward postfusion RSV-F.Keywords
All Related Versions
Funding Information
- European Research Council (101077640)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (024.002.009)
This publication has 39 references indexed in Scilit:
- Rapid simulation of glycoprotein structures by grafting and steric exclusion of glycan conformer librariesCell, 2024
- UCSF ChimeraX : Tools for structure building and analysisProtein Science, 2023
- Template-Based Assembly of Proteomic Short Reads For De Novo Antibody Sequencing and Repertoire ProfilingAnalytical Chemistry, 2022
- Deaths from RSV in young infants—the hidden community burdenThe Lancet Global Health, 2022
- Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic HypermutationImmunity, 2018
- Advances in RSV vaccine research and development – A global agendaVaccine, 2016
- The path to an RSV vaccineCurrent Opinion in Virology, 2013
- Inference of Macromolecular Assemblies from Crystalline StateJournal of Molecular Biology, 2007
- Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteriaMethods, 2006
- PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometryRapid Communications in Mass Spectrometry, 2003